Multicenter Evaluation of ABT-578 Elution From a Phosphorylcholine-coated Stent - ENDEAVOR-1
This is a drug eluting stent registry using the Medtronics Driver cobalt alloy stent with phosphorylcholine coating eluting Abbott ABT-578.
Patients Enrolled: 100
This is a multicenter-Australisian registry involving 100 patients with de novo lesions.
Lesion Diameter is 3.0 to 3.5mm
Lesion length is <15mm
Endpoints were late loss at 4 months with angiographic and intravascular ultrasound follow-up and MACE.
The Driver stent is the latest generation thin strut stent from Medtronics.
ABT-578 is a sirolimus like compound.
There was one myocardial infarction at 4 months and 1 TLR.
Late loss was 0.33mm in stent and 0.20mm in segment.
Angiographic percent diameter stenosis was 14.4% in stent and 21.7% insegment.
Neointimal volume was 61mm3 representing 4.5% of the stent volume.
The Medtronic drug eluting stent seems to be effective in the short term (4 months) except for higher than expected late loss in a low risk group of patients (low diabetes percent and larger vessel size).
Presented at Late-breaking Clinical Trials, TCT 2003, Washington, DC.
Keywords: Myocardial Infarction, Coronary Restenosis, Coronary Stenosis, Cobalt, Drug-Eluting Stents, Constriction, Pathologic, Sirolimus, Phosphorylcholine, Diabetes Mellitus
< Back to Listings